logo
Fatty Methyl Ester Sulfonate Market to Hit Valuation of US$ 2,095.1 Million by 2033

Fatty Methyl Ester Sulfonate Market to Hit Valuation of US$ 2,095.1 Million by 2033

Yahoo06-08-2025
Fuelled by surging consumer demand for green detergents, the market is experiencing robust growth, particularly in Europe and Asia. This upward trajectory, however, is persistently challenged by the volatility of key feedstock prices, creating a dynamic tension.
Chicago, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The global fatty methyl ester sulfonate market was valued at US$ 805.9 million in 2024 and is expected to reach US$ 2,095.1 million by 2033, growing at a CAGR of 11.20% during the forecast period 2025–2033.
The global fatty methyl ester sulfonate market is poised for a period of unprecedented expansion, fueled by a powerful convergence of market forces. A groundswell of consumer demand for sustainable, biodegradable, and gentle products is creating a powerful market pull. Simultaneously, increasingly stringent environmental regulations are pushing industries away from traditional, petroleum-based surfactants. This shift is amplified by significant, forward-looking investments from leading chemical and consumer goods corporations who are staking their future growth on green chemistry.
Request Sample Pages:
The result is a dynamic and rapidly evolving landscape where FMES is no longer a niche alternative but a cornerstone of next-generation product formulation. This transition is evident across the entire value chain, from raw material sourcing to end-product innovation in detergents and personal care. For stakeholders, the current climate represents a pivotal opportunity to capitalize on a market defined by sustainable growth, technological innovation, and a clear alignment with global consumer values. The future of the fatty methyl ester sulfonate market is not just promising; it is being actively constructed by these powerful, interlocking trends.
Key Findings in Fatty Methyl Ester Sulfonate Market
Market Forecast (2033)
US$ 2,095.1 million
CAGR
11.20%
Largest Region (2024)
Europe (33%)
By Application
Detergent (68%)
Top Drivers
Growing consumer demand for eco-friendly and sustainable cleaning products.
Strong demand for high-performance, biodegradable surfactants in the detergent sector.
Abundant availability of renewable feedstocks like palm and coconut oil.
Top Trends
Shift towards concentrated powder and liquid detergent formulations using FMES.
Increasing adoption in personal care formulations beyond just detergent applications.
Technological advancements in production for improved efficiency and lower costs.
Top Challenges
Fluctuating prices and inconsistent supply of essential palm oil feedstocks.
Intense competition from petroleum-based and alternative bio-based surfactants.
Complexities and higher costs associated with its production process.
Global Titans Expand Production, Signaling Robust Confidence in Bio-Based Surfactant Demand
A clear indicator of the fatty methyl ester sulfonate market's trajectory is the aggressive expansion of production capabilities by industry leaders. Evonik inaugurated a new industrial-scale rhamnolipid biosurfactant plant in Slovakia in 2024, backed by a triple-digit million-euro investment. This facility is a landmark achievement, being the first in the world to produce industrial-scale quantities of these biosurfactants. Notably, the plant in Slovenská Ľupča was completed ahead of its original schedule, underscoring the urgency of market demand. Similarly, Locus Fermentation Solutions expanded its operational footprint by 100,000 square feet with two new biomanufacturing facilities, effectively increasing its biological production capacity by a factor of three.
These new facilities boast a potential future annual production capacity of 2.5 million kilograms of biosurfactants, enabled by a patented fermentation technology that allows new production sites to become operational within just nine months. Further cementing this trend, KLK Oleo announced in July 2024 an expansion of its oleochemicals processing capacity in Zhangjiagang, China, to 500,000 tons annually. This build-out is aimed at serving the over 700 detergent production sites across Europe as of early 2025, a vast customer base for which Henkel is a prime example, having converted 14 additional sites to carbon-neutral production in 2023 with more planned for 2024/2025.
Shifting International Trade Winds Create New Opportunities in Key Regional Surfactant Markets
The global trade dynamics for raw materials and finished goods provide a quantitative lens into regional demand hotspots of the fatty methyl ester sulfonate market. In January 2025, Malaysia's total palm oil exports, a key feedstock, were recorded at 1.17 million tons, a decrease from the 1.34 million tons exported in December 2024. However, exports of Malaysian oleochemicals, a category intrinsically linked to the market, stood at a significant 232,567 tons in that same month. A particularly bright spot is the United States, where Malaysia's palm oil exports from January to May 2025 reached 93,000 tons, a substantial increase from the 61,000 tons during the same period in the previous year.
In Europe fatty methyl ester sulfonate market, which imported a total of 7.19 million tons of long products from third countries in 2024, Romania emerged as a key importer, receiving 1.19 million tons. Focusing on surfactants directly, the United States imported 896 shipments between November 2023 and October 2024. In the last 12 months, a staggering 3,983 U.S. importers have utilized the HTS code 3402 for surface-active agents, sourcing from 2,964 foreign suppliers, illustrating a deeply fragmented and active import landscape. This activity occurs within the context of the European Union's massive import economy, which was valued at US$2.64 Trillion in 2024.
Navigating the Volatile Raw Material Landscape: A Critical Factor for Market Stability
The cost and availability of feedstocks are paramount to the profitability and stability of the FMES sector in the fatty methyl ester sulfonate market. In January 2025, Malaysia's crude palm oil (CPO) production was 1.24 million tons, with palm kernel output reaching 290,883 tons. Critically, total palm oil stocks in the country declined to 1.58 million tons in that month, a factor that can influence price dynamics. Beyond palm oil, the price of other chemical inputs is also a key consideration. Ethylene oxide prices in Germany were recorded at 1357 USD/MT in June 2024, while in Saudi Arabia, they were priced at 1294 USD/MT. The United States saw a higher price point, reaching 1398 USD/MT for ethylene oxide in June 2024. Meanwhile, in the competitive Chinese market, ethylene oxide prices settled around 913 USD/MT in May 2025, highlighting regional price disparities that impact production costs globally.
Green Detergent Revolution: A Primary Demand Driver for High-Performance, Eco-Friendly Surfactants
The detergents segment of the fatty methyl ester sulfonate market remains the bedrock of demand, with a pronounced shift toward green formulations. The European bio-based surfactants market volume was estimated at a substantial 197,400.6 tons in 2024, with projections showing a climb to 277,802.9 tons by 2034. The household detergents segment is the dominant force, accounting for approximately 35% of the bio-based surfactants market in 2024. This trend is reflected in product innovation, with a 2024 Kantar survey of 40,000 people naming a new hypoallergenic scent detergent, all® sensitive fresh™, a winner in its category. This specific liquid detergent, available in 36-ounce (24 loads) and 88-ounce (58 loads) bottles, is formulated to remove 99% of top everyday and seasonal allergens.
Consumer interest is quantifiable, with online searches for "gentle detergent" showing a steady volume of 720 web searches per month from December 2023 to August 2024. The market is responding with products like 9 Elements, which offers a liquid laundry detergent with a maximum of nine ingredients, and at least 6 new major natural or sensitive-skin-focused laundry detergents were highlighted by lifestyle publications in 2024 alone.
The Clean Beauty Movement Propels Adoption of Milder, Sustainable Ingredients in Cosmetics
The personal care sector is emerging as the fastest-growing application for bio-based surfactants, directly benefiting the fatty methyl ester sulfonate market. This growth is fueled by rising consumer spending; the average U.S. consumer expenditure on personal care products and services reached $950 in 2023, up from $866 the previous year. In Europe, personal care applications accounted for a significant 16% of surfactant volume consumption in 2024, demonstrating the ingredient's importance in the region. The digital marketplace is a key battleground, with the North America online beauty and personal care market size estimated at a massive USD 22,061.68 million in 2024, providing a vast platform for products formulated with sustainable surfactants like FMES.
Massive Corporate Investments in Green Chemistry and R&D Shape Future Market Leadership
Corporate capital is flowing decisively towards sustainable solutions, underwriting the growth of the entire bio-surfactant ecosystem. Unilever is investing €150 million over the next three years in its manufacturing decarbonization program and has already spent and committed €300 million of its €1 billion climate, nature, and waste reduction fund by the end of 2023. Furthermore, Unilever, one of the key players in the fatty methyl ester sulfonate market, is investing €325 million in its Indonesian oleochemicals facility to guarantee a supply of deforestation-free commodities.
R&D powerhouse BASF reported research and development expenses of €2,061 million in 2024 and filed 1,159 new patents in the same year. This R&D engine, powered by approximately 10,000 employees, generated around €11 billion in sales in 2024 from products launched in the last five years. Evonik is also making bold moves, aiming to invest over €3 billion in its "Next Generation Solutions," which explicitly include sustainable biosurfactants, by 2030. Meanwhile, Locus Fermentation Solutions secured $117 million in IP-insurance-backed debt financing in early 2023, bringing its total raised funds to over $250 million.
Stringent New Environmental Regulations Compel a Strategic Shift Towards Greener Chemical Alternatives
The regulatory landscape of the fatty methyl ester sulfonate market is becoming a powerful catalyst for change. On June 14, 2025, the EU Council and Parliament reached a provisional agreement to update the Regulation on Detergents and Surfactants. This new EU regulation mandates digital labeling, making information like fragrance allergens more transparent to consumers. Furthermore, as of October 17, 2025, suppliers of microplastics for industrial use in the EU must provide instructions on preventing their release into the environment, part of a wider goal to reduce microplastics pollution by 30% by 2030.
The EU's updated Urban Wastewater Directive, effective January 1, 2025, now requires systematic monitoring of microplastics at treatment plants. To ensure compliance, non-EU manufacturers of detergents will be required to appoint an authorized representative in the EU under the new 2025 regulations. Trade policies will also play a role, with a new US tariff of 25% on certain Malaysian goods set to come into effect on August 1, 2025, potentially influencing supply chain decisions within the fatty methyl ester sulfonate market.
Corporate Sustainability Pledges Creating Unprecedented, Long-Term Demand for Eco-Conscious Supply Chains
Beyond regulatory compliance, corporate sustainability goals are creating durable, long-term demand for ingredients like FMES. Unilever is targeting a 100% reduction in its Scope 1 and 2 emissions by 2030 (from a 2015 baseline) and aims to engage 300 of its most emissions-intensive suppliers in its Supplier Climate Programme by the end of 2024. The company has a broader goal to achieve net-zero emissions across its value chain by 2039. Similarly, Henkel has committed to reducing the amount of virgin plastics from fossil sources in its consumer products by 50% by 2025 and has set a goal for 100% of its packaging to be designed for recyclability or reusability by the same year; by the end of 2024, this figure had already reached an impressive 89%.
Henkel also increased the proportion of recycled plastic in its consumer goods packaging to 25% globally as of its 2024 report and is on track to meet its palm oil targets, having sourced 97% of its requirements as certified material in 2024 toward a 100% goal by 2025. In production, Henkel reduced CO2 emissions by 64% per ton of product since 2017, as reported in 2025.
Customize the Data Scope to Match Your Objectives:
Technological Breakthroughs and Consumer Awareness Converge to Redefine Market Success Factors
Innovation in both production and consumer perception is setting a new bar for success in the fatty methyl ester sulfonate market. Patented technological advancements are refining efficiency and performance. A Chinese patent (CN114605293B), for example, details a specific preparation process for FMES using a mass ratio of sulfur trioxide to fatty acid methyl ester of 1.25:1. The same patent outlines the use of a viscosity modifier at a dosage of 0-20% of the mass of the fatty acid methyl ester sulfonic acid. Another patent for liquid detergent (EP 2029709 B1) specifies an optimal pH range for the methyl ester sulfonates feed composition of about 6.5 to 7.5. These technical refinements are meeting a market where consumer awareness is at an all-time high.
The all® free clear detergent brand holds the powerful distinction of being the #1 recommended detergent by dermatologists, allergists, and pediatricians for sensitive skin. This consumer trust is the ultimate currency, built not just on product performance but on corporate values. In a nod to broader ESG trends that resonate with modern consumers, Henkel reported in 2025 that 42% of its management roles were held by women, reflecting a commitment to values that extend beyond the chemical formula.
Global Fatty Methyl Ester Sulfonate Market Major Players:
BASF
Chemithon Corporation
Emery Oleochemicals
FENCHEM
KLK Oleo
KPL International Ltd
Lion Corporation
PT Ecogreen Oleochemicals
Sinopec Jinling Petrochemical
Stepan Company
Surface Chemical Industry Co Ltd
Wilmar International Ltd
Other Prominent Players
Key Market Segmentation:
By Application
Personal Care
Detergents
Others
By Region
North America
Europe
Asia Pacific
Middle East
Africa
South America
Want Clarity on Report Coverage? Schedule a Quick Demo Call:
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@astuteanalytica.comWebsite: https://www.astuteanalytica.com/ Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/Sign in to access your portfolio
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Yahoo

time23 minutes ago

  • Yahoo

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech's history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market Conference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT) REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the 'Company'), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT). 'The strong results from the first half of the year, with over 200% increase in product revenues year-on-year and the best quarter in our history in terms of operating cash flows, confirm our business momentum and the opportunities that lie ahead. New and expanded partnership agreements reflect the value of our increased development activity. The recent acquisition of Xbrane's R&D facilities in Sweden allows us to further ramp up development of new biosimilars and continue building the industry's most valuable pipeline. With our acquisition of Ivers-Lee Group in Switzerland in July, we continue integration of our end-to-end biosimilars platform,' said Robert Wessman, Chairman and CEO of Alvotech. Activity in Q2 2025 Commercial Agreements Alvotech entered into two agreements to expand the commercial partnership with Advanz Pharma, covering four biosimilar candidates, AVT48, referencing Ilaris® (canakinumab), AVT65, referencing Kesimpta® (ofatumumab), AVT10, referencing Cimzia® (certolizumab pegol), plus an undisclosed biosimilar candidate. Alvotech also announced that it had entered into a collaboration and license agreement with Dr. Reddy's Laboratories Ltd. to co-develop, manufacture and commercialize AVT32, a biosimilar candidate to Keytruda® (pembrolizumab). The collaboration is intended to speed up the development process and extend the global reach of this biosimilar candidate. The parties will be jointly responsible for development and manufacturing, sharing costs and responsibilities. Each party will also have the right to commercialize the product globally, subject to certain exceptions. Acquisitions and Funding Alvotech completed its transaction with Xbrane Biopharma AB ('Xbrane') with the acquisition of its R&D organization in Stockholm, Sweden and rights to a biosimilar candidate to Cimzia® (certolizumab pegol), now known as AVT10. After the end of the second quarter, in July, Alvotech acquired Ivers-Lee Group ('Ivers-Lee'), a family-owned business with headquarters in Burgdorf, Switzerland specializing in providing high-quality assembly and packaging services for the pharmaceutical sector. Ivers-Lee operations will be integrated into Alvotech's Technical Operations division. Among Ivers-Lee's capacities that will be integrated with Alvotech's operations are assembly and packaging of autoinjectors, pre-filled syringes and safety devices and packaging of vials. Alvotech completed two offerings of Swedish Depository Receipts ('SDRs'), with a public offering directed solely into Sweden, generating gross proceeds of approximately SEK 39 million and a private placement directed to Swedish and international institutional investors, generating gross proceeds of SEK 750 million. Over 3,000 new shareholders participated in the public offering and 40 institutional investors participated in the private placement. On May 19, 2025, Alvotech was listed on Nasdaq Stockholm. This is Alvotech's third listing, complementing previous listings on Nasdaq in the US and Iceland. Alvotech entered into an amendment to its existing term loan credit agreement, which provides, among other things, for the reduction of the interest rate, lowering interest expenses by $8.2 million in the first 12 months. Based on the amended agreement the loan consists of a single tranche with an interest rate of SOFR plus 6.0%. Changes to Management On July 9, 2025, Linda Jónsdóttir was appointed Chief Financial Officer, replacing Joel Morales who continues to serve in an advisory function. Linda is a highly experienced international executive with a strong background in finance and corporate leadership, including holding senior roles for 15 years at Marel, such as Director of Treasury and Investor Relations, Chief Financial Officer and Chief Operating Officer. Linda has also served on various boards, in banking, private equity funds and at the Icelandic Chamber of Commerce. Summary of the financial results for the first six months of 2025 Cash position and sources of liquidity: As of June 30, 2025, the Company had cash and cash equivalents of $151.5 million. This strong cash position was positively impacted by robust operational performance, including significant product revenue growth and milestone collections, as well as the successful completion of a Swedish private placement that raised gross proceeds of approximately SEK 789 million. In addition, the Company had borrowings of $1,118.2 million, including $46.0 million of current portion of borrowings. Product Revenue: Product revenue was $204.7 million for the six months ended June 30, 2025, compared to $65.9 million for the six months ended June 30, 2024, reflecting the sales expansion of AVT02 in the U.S., Canada, and European countries, as well as the increased sales of AVT04 in European countries, and the launch of AVT04 in the U.S. License and Other Revenue: License and other revenue was $101.3 million for the six months ended June 30, 2025, compared to $169.7 million for the six months ended June 30, 2024. The year-over-year decrease primarily reflects the timing of milestone achievements, with the prior-year period including significant research and development and performance-based milestones totaling $133.2 million. In the current period, license and other revenue was supported by the completion of key development phases, including $36.8 million related to completion of early development phase for multiple pipeline program, and $21.3 million for the completion of a clinical endpoint study for the AVT23 program. Additionally, $12.8 million was recognized from the achievement of sales targets for AVT04 in Europe and its launch in the U.S. Cost of product revenue: Cost of product revenue was $139.3 million for the six months ended June 30, 2025, compared to $65.2 million for the six months ended June 30, 2024. The increase reflects higher sales volumes driven by the continued expansion of AVT02 in the U.S. and the launch and expansion of AVT04 across multiple markets, including the U.S. and European countries. This increase was partially offset by lower production-related charges, reflecting improved operational efficiency. Research and development (R&D) expenses: R&D expenses were $92.9 million for the six months ended June 30, 2025, compared to $97.5 million for the six months ended June 30, 2024. The modest year-over-year decrease reflects the natural progression of Alvotech's pipeline, with several programs transitioning out of the clinical phase (i.e. AVT03, AVT05, and AVT06) or reaching commercialization (i.e., AVT04). These reductions were partially offset by increased investment in advancing clinical programs, notably AVT16 and AVT29, which contributed to a $33.1 million rise in direct program expenses. General and administrative (G&A) expenses: G&A expenses were $45.3 million for the six months ended June30, 2025, compared to $29.6 million for the six months ended June 30, 2024. The increase in G&A expenses was primarily driven by an increase of $13.6 million in third-party services costs, which included legal fees related to ongoing intellectual property proceedings and advisory costs associated with the Company's Swedish listing and the acquisition of Xbrane's operations. Operating profit: Operating profit was $28.6 million for the six months ended June 30, 2025, compared to $43.4 million for the same period in the prior year. The year-over-year decrease reflects the timing of milestone-related revenue recognized in the prior period, partially offset by increased product sales across key markets. The Company continued to invest strategically in commercialization efforts, regulatory advancement, and pipeline development, positioning Alvotech for long-term growth and operational scale. Finance income: Finance income was $149.2 million for the six months ended June 30, 2025, compared to $80.8 million for the six months ended June 30, 2024. Finance income for the six months ended June 30, 2025 was primarily attributable to the change in fair value of derivative liabilities, which was positively impacted by the decrease in the Company's share price during the period. Finance costs: Finance costs were $72.2 million for the six months ended June 30, 2025, compared to $277.4 million for the six months ended June 30, 2024. The current period's finance costs primarily reflect interest charges on outstanding debt of $1,118.2 million. The prior-year period included $130.4 million in non-cash charges related to the fair value of derivative liabilities, which were negatively impacted by an increase in Alvotech's share price, and $79.1 million in interest charges on debt of $1,055.9 million. Additionally, the early redemption of existing debt in connection with the July 2024 refinancing resulted in a $63.1 million loss on remeasurement due to the acceleration of previously deferred debt issuance costs and discounts in the six months ended June 30, 2024. The year-over-year reduction in finance costs reflects the Company's proactive capital structure management and the transition to a more efficient financing arrangement. Exchange rate differences: Exchange rate differences resulted in a loss of $19.7 million for the six months ended June 30, 2025, compared to a gain of $7.7 million for the six months ended June 30, 2024. The change was primarily driven by fluctuations in foreign currency exchange rates, notably between the Icelandic krona and the U.S. dollar. Gain on modification and extinguishment of financial liabilities: On June 26, 2025, Alvotech announced an amendment to its existing term loan facility, reflecting continued efforts to optimize its capital structure. Under the revised agreement, the Company's lenders agreed to reduce the interest rate to SOFR plus 6.0% and consolidate the facility's two tranches into a single tranche, with an increase of $169.0 to the single tranche. As a result of the amendment, Alvotech recorded a net gain of $16.7 million on the modification and extinguishment of financial liabilities during the six months ended June 30, 2025, primarily driven by the reduction of the interest rate to SOFR plus 6.0% per annum. Income tax benefit / (expense): Income tax benefit was $39.0 million for the six months ended June 30, 2025, compared to an income tax expense of $5.1 million for the six months ended June 30, 2024. The favorable variance was primarily driven by a $47.4 million tax benefit resulting from the strengthening of the Icelandic krona against the U.S. dollar, which increased the U.S. dollar value of Icelandic tax loss carryforwards, which the Company expects to utilize against future taxable profits. This benefit was partially offset by a $3.7 million tax expense related to profitability generated in Iceland during the period. Profit / (loss) for the Period: Reported net profit was $141.7 million, or $0.50 per share and $0.49 per share on a basic and diluted basis, respectively, for the six months ended June 30, 2025, compared to a reported net loss of $153.5 million, or ($0.61) per share on a basic and diluted basis, for the six months ended June 30, 2024. The significant increase reflects strong growth in product revenue, favorable movements in the fair value of derivative liabilities, and lower finance costs following the Company's capital structure optimization. Business update conference call Alvotech will conduct a business update conference call and live webcast on Thursday, August 14, at 8:00 am ET (12:00 noon GMT). Registration for the conference call and access to the live webcast is found on where you will also be able to find a replay of the webcast, following the call for 90 days. About AVT02 (adalimumab) AVT02 is a monoclonal antibody and has been approved as a biosimilar to Humira® (adalimumab) in over 50 countries globally, including the U.S., Europe, Canada, Australia, Egypt, Saudi Arabia and South Africa. It is currently marketed in the U.S. as SIMLANDI and under private label (adalimumab-ryvk), in Europe as HUKYNDRA, in Canada as SIMLANDI and in Australia as ADALICIP. Dossiers are also under review in multiple countries globally. About AVT03AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia® and Xgeva® (denosumab). Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction [1]. AVT03 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT04 (ustekinumab) AVT04 is a monoclonal antibody and a biosimilar to Stelara® (ustekinumab). AVT04 has been launched in Canada as JAMTEKI, in the EEA as UZPRUVO, in Japan as USTEKINUMAB BS (F) and in the U.S. as SELARSDI (ustekinumab-aekn). Dossiers are also under review in multiple countries globally. About AVT05 AVT05 is a biosimilar candidate for Simponi® and Simponi Aria® (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha). Elevated TNF alpha levels have been implicated in the pathophysiology of several chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [2]. AVT05 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT06/AVT29AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept) in different dosing strength which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability [3]. AVT06/AVT29 are investigational products and have not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT10AVT10 is a proposed biosimilar to Cimzia® (certolizumab pegol). Certolizumab pegol is a monoclonal antibody fragment that inhibits tumor necrosis factor alpha (TNF alpha) and is indicated for a variety of inflammatory diseases [4]. AVT10 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT16 AVT16 is a human monoclonal antibody and a biosimilar candidate to Entyvio® (vedolizumab). Vedolizumab targets and binds specifically to the alpha-4-beta-7 protein, which is preferentially expressed on T helper lymphocytes (white blood cells) which migrate into the gastrointestinal tract and cause inflammation characteristic of Ulcerative Colitis and Chron's disease [5]. AVT16 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT23AVT23 is a proposed biosimilar to Xolair® (omalizumab). Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E (IgE). Xolair, which contains omalizumab, is indicated for severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) [6]. AVT23 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT32AVT32 is a biosimilar candidate for Keytruda® (pembrolizumab). Pembrolizumab is a humanized monoclonal antibody that binds to the programmed death receptor-1 (PD-1 receptor) and is indicated for the treatment of several types of cancers [7]. AVT32 is an investigational compound and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT48AVT48 is a biosimilar candidate for Ilaris® (canakinumab). Canakinumab is a recombinant monoclonal antibody that binds to human immunoglobulin (IL) 1-beta, and is indicated for the treatment of several systemic autoinflammatory diseases [8]. AVT48 is an investigational compound and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. About AVT65AVT65 is a biosimilar candidate for Kesimpta® (ofatumumab). Ofatumumab is a CD20-directed cytolytic antibody and is indicated for the treatment of relapsing forms of multiple sclerosis (MS). AVT65 is an investigational compound and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. Sources [1] Prolia product information[2] Simponi product information[3] Eylea product information[4] Cimzia product information[4] Entyvio product information[5] Xolair product information[7] Keytruda product information[8] Ilaris product information[9] Kesimpta product information Use of trademarks Stelara®, Simponi® and Simponi Aria® are registered trademarks of Johnson & Johnson. Humira® is a registered trademark of AbbVie Biotechnology Ltd. Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc and Bayer AG. Prolia® and Xgeva® are registered trademarks of Amgen Inc. JAMTEKI™ is a trademark of JAMP Pharma Group. UZPRUVO® and HUKYNDRA® are registered trademarks of STADA and Alvotech. ADALICIP is a registered trademark of Cipla Australia. Xolair®, Ilaris® and Kesimpta® are registered trademarks of Novartis AG. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp. Cimzia® is a registered trademark of UCB Pharma S.A. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking Statements Certain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to maintain positive EBITDA and positive cash flows from operations; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements made herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS Benedikt Stefansson, Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss for the six months ended 30 June 2025 and 2024 USD in thousands, except for per share amounts Six months ended 30June 2025 Six months ended 30June 2024 Product revenue 204,733 65,912 License and other revenue 101,271 169,678 Other income 143 57 Cost of product revenue (139,272 ) (65,167 ) Research and development expenses (92,889 ) (97,479 ) General and administrative expenses (45,347 ) (29,554 ) Operating profit 28,639 43,447 Loss on sale of interest in joint venture — (2,970 ) Finance income 149,247 80,823 Finance costs (72,190 ) (277,414 ) Exchange rate differences (19,683 ) 7,742 Gain on modification and extinguishment of financial liabilities 16,718 — Non-operating profit / (loss) 74,092 (191,819 ) Profit / (loss) before taxes 102,731 (148,372 ) Income tax benefit / (expense) 38,987 (5,132 ) Profit / (loss) for the period 141,718 (153,504 ) Other comprehensive profit / (loss) Item that will be reclassified to profit or loss in subsequent periods: Exchange rate differences on translation of foreign operations 3,434 121 Total comprehensive profit / (loss) 145,152 (153,383 ) Profit / (loss) per share Basic profit / (loss) for the period per share 0.50 (0.61 ) Diluted profit / (loss) for the period per share 0.49 (0.61 ) Unaudited Condensed Consolidated Interim Statements of Financial Position as of 30 June 2025 and 31 December 2024 USD in thousands Non-current assets 30 June2025 31 December2024 Property, plant and equipment 306,596 284,546 Right-of-use assets 134,481 125,198 Goodwill 12,790 11,330 Other intangible assets 54,688 20,621 Contract assets 32,070 22,710 Other long-term assets 4,338 3,615 Deferred tax assets 338,330 298,360 Total non-current assets 883,293 766,380 Current assets Inventories 155,490 127,889 Trade receivables 108,103 160,217 Contract assets 46,664 67,304 Other current assets 47,579 48,064 Receivables from related parties 173 118 Cash and cash equivalents 151,452 51,428 Total current assets 509,461 455,020 Total assets 1,392,754 1,221,400 Unaudited Condensed Consolidated Interim Statements of Financial Position as of 30 June 2025 and 31 December 2024 USD in thousands Equity 30 June 2025 31 December 2024 Share capital 2,924 2,826 Share premium 2,102,896 2,007,058 Other reserves 15,627 17,272 Translation reserve 1,216 (2,218 ) Accumulated deficit (2,295,991 ) (2,437,709 ) Total equity (173,328 ) (412,771 ) Non-current liabilities Borrowings 1,072,138 1,035,882 Derivative financial liabilities 63,004 210,224 Lease liabilities 136,263 112,137 Contract liabilities 12,914 80,721 Deferred tax liability 2,014 1,811 Total non-current liabilities 1,286,333 1,440,775 Current liabilities Trade and other payables 84,282 67,126 Lease liabilities 13,591 9,515 Current maturities of borrowings 46,026 32,702 Liabilities to related parties 1,641 8,465 Contract liabilities 60,333 15,980 Taxes payable 741 204 Other current liabilities 73,135 59,404 Total current liabilities 279,749 193,396 Total liabilities 1,566,082 1,634,171 Total equity and liabilities 1,392,754 1,221,400 Unaudited Condensed Consolidated Interim Statements of Cash Flows for the six months ended 30 June 2025 and 2024 USD in thousands Cash flows from operating activities Six months ended 30June 2025 Six months ended 30June 2024 Profit (loss) for the period 141,718 (153,504 ) Adjustments for non-cash items: Depreciation and amortization 17,156 14,748 Change in inventory reserves 5,238 (6,936 ) Change in allowance for receivables 703 — Share-based payments 3,418 5,294 Loss on sale of interest in joint venture — 2,970 Gain on modification and extinguishment of financial liabilities (16,718 ) — Finance income (149,247 ) (80,823 ) Finance costs 72,190 277,414 Exchange rate difference 19,683 (7,742 ) Income tax benefit (38,987 ) 5,132 Operating cash flow before movement in working capital 55,154 56,553 Increase in inventories (32,839 ) (15,205 ) Decrease / (increase) in trade receivables 51,411 (52,229 ) (Increase) / decrease in receivables with related parties (55 ) 92 Decrease / (increase) in contract assets 13,624 (27,179 ) (Increase) / decrease in other assets (990 ) 369 Increase / (decrease) in trade and other payables 17,757 (21,758 ) Decrease in contract liabilities (31,743 ) (35,881 ) (Decrease) / increase in liabilities with related parties (3,917 ) 16,677 Increase / (decrease) in other liabilities 8,127 (6,056 ) Cash from (used in) operations 76,529 (84,617 ) Interest received 50 26 Interest paid (8,039 ) (41,037 ) Income tax paid (249 ) (372 ) Net cash from (used in) operating activities 68,291 (126,000 ) Cash flows from investing activities Acquisition of property, plant and equipment (36,805 ) (10,271 ) Acquisition of intangible assets (15,168 ) (1,430 ) Restricted cash in connection with amended bond agreement — 1,132 Proceeds from the sale in joint venture 2,975 — Net cash used in investing activities (48,998 ) (10,569 ) Cash flows from financing activities Six months ended 30June 2025 Six months ended 30June 2024 Repayments of borrowings (7,757 ) (75,059 ) Repayments of principal portion of lease liabilities (4,924 ) (4,815 ) Proceeds from new borrowings 11,267 67,500 Gross proceeds from equity offering 82,481 150,451 Fees from equity offering (3,759 ) (5,812 ) Proceeds from warrants — 4,841 Stock options exercised — 76 Net cash generated from financing activities 77,308 137,182 Increase in cash and cash equivalents 96,601 613 Cash and cash equivalents at the beginning of the year 51,428 11,157 Effect of movements in exchange rates on cash held 3,423 (826 ) Cash and cash equivalents at the end of the period 151,452 10,944 Sign in to access your portfolio

Sensata Technologies, Vishay Intertechnology, Power Integrations, Entegris, and Amtech Shares Skyrocket, What You Need To Know
Sensata Technologies, Vishay Intertechnology, Power Integrations, Entegris, and Amtech Shares Skyrocket, What You Need To Know

Yahoo

time23 minutes ago

  • Yahoo

Sensata Technologies, Vishay Intertechnology, Power Integrations, Entegris, and Amtech Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after the semiconductor sector continued to rally as a favorable July inflation report boosted investor confidence for a potential Federal Reserve interest rate cut in September. Lower-than-expected inflation data for July increased market expectations for a Federal Reserve interest rate cut next month, with futures markets pricing in a 96.2% probability. A potential rate cut lowers borrowing costs, which is particularly beneficial for growth-oriented sectors like technology and semiconductors as it can fuel investment and expansion. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Analog Semiconductors company Sensata Technologies (NYSE:ST) jumped 5.6%. Is now the time to buy Sensata Technologies? Access our full analysis report here, it's free. Analog Semiconductors company Vishay Intertechnology (NYSE:VSH) jumped 4.4%. Is now the time to buy Vishay Intertechnology? Access our full analysis report here, it's free. Analog Semiconductors company Power Integrations (NASDAQ:POWI) jumped 4.3%. Is now the time to buy Power Integrations? Access our full analysis report here, it's free. Semiconductor Manufacturing company Entegris (NASDAQ:ENTG) jumped 5%. Is now the time to buy Entegris? Access our full analysis report here, it's free. Semiconductor Manufacturing company Amtech (NASDAQ:ASYS) jumped 6.9%. Is now the time to buy Amtech? Access our full analysis report here, it's free. Zooming In On Amtech (ASYS) Amtech's shares are very volatile and have had 23 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 12 days ago when the stock dropped 3.3% on the news that the U.S. jobs report for July came in significantly weaker than expected while new widespread import tariffs were announced, sparking fears of a potential economic slowdown. The U.S. economy added only 73,000 jobs, far below estimates, and massive downward revisions to the prior two months painted a much weaker picture of the labor market. This has stoked recession fears, which would directly impact demand for chips used in countless products. Compounding these worries, the White House announced new tariffs, including a 20% levy on imports from Taiwan, a global hub for chip manufacturing. This dual shock of slowing domestic growth and renewed trade friction creates a challenging outlook for the highly cyclical and globally connected semiconductor industry, leading to a broad-based sell-off. Amtech is down 11.8% since the beginning of the year, and at $4.94 per share, it is trading 26.7% below its 52-week high of $6.74 from August 2024. Investors who bought $1,000 worth of Amtech's shares 5 years ago would now be looking at an investment worth $997.98. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Fed's Goolsbee signals door open to rate cut in fall
Fed's Goolsbee signals door open to rate cut in fall

Yahoo

time23 minutes ago

  • Yahoo

Fed's Goolsbee signals door open to rate cut in fall

By Ann Saphir (Reuters) -Chicago Federal Reserve Bank President Austan Goolsbee said on Wednesday he is uneasy assuming that tariffs will not push up inflation and is unconvinced that the U.S. labor market is deteriorating. Those premises have been cited by a few of his colleagues for supporting interest rate cuts by the U.S. central bank. However, Goolsbee left the door wide open to aligning with them by the Fed's September 16-17 policy-setting meeting. "All of the meetings this fall, they are going to be live meetings," with decisions based on the latest data, Goolsbee told reporters after a speech. "I'm not implying that I can't reach a decision by meetings that are coming up, because like I say, we're going to get some good and important pieces of information that I'm going to add to the ones that we've gotten for the last three months." If inflation is convincingly falling and the labor market is cooling, "that's not hard ... when things are cooling the Fed tries to act countercyclically," he said. The Fed left short-term borrowing costs in the 4.25%-4.50% range at its July 29-30 meeting, drawing dissents from Vice Chair of Supervision Michelle Bowman and Governor Christopher Waller who wanted to cut rates to head off what they worried was incipient labor market weakness. To Goolsbee, the signs are more mixed. While monthly job gains, after recent revisions, slowed sharply in the last three months to an average of 35,000, the drop could very well reflect a decline in immigration rather than an underlying weakening in demand, he said. Other data like the unemployment rate of 4.2% and low layoff rate suggest the labor market remains solid, he said. Goolsbee also said he needs to see multiple months of good inflation readings to feel comfortable about a rate cut. "I envision we're going to keep learning information and keep going on the path; the more convincing it is that we are on path to 2% inflation, the faster I think we can go to what is r-star," he added, using an economists' term for the level at which interest rates should settle when the economy is running neither too hot or cold. "You could cut, one, in anticipation if you think you're on the path, as long as you're laying out the criteria of what you're doing ... and if we start getting information that contradicts that then we would stop cutting or go the other way: that's an entirely possible path, outcome, or whatever you want to call it," he said. "The way I think of it is not a cliff - it's not, I'm going to reach an epiphany one day," he said, and cut rates immediately to where they are expected to settle in the long term, which Fed policymakers generally estimate is around 3%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store